D.E. Shaw & Co’s Ascendis Pharma A/S ASND Stock Holding History

D.E. Shaw & Co’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11M	Buy	48,100 +42,400	+744%	+$9.5M	0.01%	1550
2025 Q4	$1.22M	Buy	5,700 +700	+14%	+$145K	﹤0.01%	3412
2025 Q3	$994K	Hold	5,000	–	–	﹤0.01%	3466
2025 Q2	$863K	Hold	5,000	–	–	﹤0.01%	3323
2025 Q1	$779K	Hold	5,000	–	–	﹤0.01%	3244
2024 Q4	$688K	Hold	5,000	–	–	﹤0.01%	3428
2024 Q3	$747K	Buy	+5,000	New	+$675K	﹤0.01%	3470

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co's ASND Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Ascendis Pharma A/S (ASND) stake by 99% in Q1 2026, selling an estimated $28M and leaving 1,062 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #4143.

D.E. Shaw & Co first reported a position in ASND in Q1 2018 and has held it in 33 quarters since. The position peaked at $51.4M in Q1 2024. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

D.E. Shaw & Co held 1,062 shares of Ascendis Pharma A/S worth $243K as of Q1 2026.
D.E. Shaw & Co sold 124,706 Ascendis Pharma A/S shares in Q1 2026, an estimated $28M.
Ascendis Pharma A/S made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4143 holding.
D.E. Shaw & Co first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 33 quarters since.
D.E. Shaw & Co's Ascendis Pharma A/S position peaked at $51.4M in Q1 2024.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.